FDA Announcement On Makena Will Allow All Women To Continue To Receive Affordable Treatment To Prevent Pre-Term Birth
The Society for Maternal-Fetal Medicine (SMFM) weighed in on the FDA announcement to continue to allow pharmacies to compound hydroxyprogesterone caproate, also known as 17P. This FDA announcement comes in response to an outcry from SMFM, ACOG and others regarding the costs of the just-released pharmaceutical version of the drug. The new drug, Makena, made by KV Pharmaceuticals, is being sold at ...

Boehringer Ingelheim Pharmaceuticals, Inc. Statement Regarding FDA Approval Of Viramune XR Extended-Release Tablets
The U.S. Food and Drug Administration (FDA) has approved Viramune XR (nevirapine) extended-release tablets, to be used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. VIRAMUNE XR is a one-pill, once-daily (400 mg) formulation of nevirapine. VIRAMUNE was approved by the FDA in 1996. Boehringer Ingelheim (BI) is committed to improving HIV therapy ...